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A b s t r a c t
Multiple sclerosis (MS) is a  human autoimmune neurodegenerative disease with an unknown etiology. Despite 
various therapies, there is no effective cure for MS. Since the mechanism of the disease is based on autoreactive 
T-cell responses directed against myelin antigens, oral tolerance is a promising approach for the MS treatment. Here, 
the experiments were performed to assess the impact of oral administration of recombinant Lactococcus lactis pro-
ducing encephalogenic fragments of three myelin proteins: myelin basic protein, proteolipid protein, and myelin oligo-
dendrocyte glycoprotein, on neuroimmunological changes in rats with experimental allergic encephalomyelitis (EAE) 
– an animal model of MS. 
Lactococcus lactis whole-cell lysates were administered intragastrically at two doses (103 and 106 colony forming 
units) in a twenty-fold feeding regimen to Lewis rats with EAE. Spinal cord slices were subjected to histopatho-
logical analysis and morphometric evaluation, and serum levels of cytokines (IL-1b, IL-10, TNF-α and IFN-γ) were 
measured. Results showed that administration of the L. lactis preparations at the tested doses to rats with EAE, 
diminished the histopathological changes observed in EAE rats and reduced the levels of serum IL-1b, IL-10 and 
TNF-α, previously increased by evoking EAE. This suggests that oral delivery of L. lactis producing myelin peptide 
fragments could be an alternative strategy to induce oral tolerance for the treatment of MS.
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Introduction
Multiple sclerosis (MS) is an autoimmune dis-
ease that targets young people (20-40 years old) 
and is more common in women than in men. It is 
most frequently encountered in Northern Europe 
and North America, affecting approximately 1 in 1000 
people. The genesis of MS remains unknown, but 
some evidence has supported the contributions of 
genetic and environmental factors or viral infection 
[35]. Despite its unidentified origin, the mechanism 
of MS involves humoral and cellular immunity and 
is based on T-cell autoreactivity directed against 
myelin antigens. Autoreactive T-lymphocytes migrate 
through the open blood-brain barrier into the central 
nervous system (CNS), where they recognize myelin 
proteins as pathogenic and induce an antigen-spe-
cific inflammatory process. Inflammation directed 
against myelin proteins causes demyelination and 
further deterioration of axons or even whole neu-
rons, which results in deceleration or disruption of 
neurotransmission [12]. Tissue injury also affects 
oligodendrocytes function due to glutamatergic exci-
totoxicity in the sites of inflammatory lesions [10]. 
CNS damage provokes progressive physical disability 
and associated mental impairment that occur in MS 
patients. Currently, there is no effective therapy for 
MS. The most common treatment is systemic immu-
nosuppression, which may also weaken the immune 
system and expose the patient to frequent infections 
[3,12,42]. However, new therapies targeting specific 
mechanisms involved in the pathology of MS, such as 
natalizumab, alemtuzumab or daclizumab may cause 
severe side effects or result in lower efficiencies 
than previously expected [7-9]. Thus, there is a need 
to identify novel therapies that are more effective 
and safe for patients. Among the most promising 
approaches developed in recent years that could 
potentially be applied for the treatment of autoim-
mune diseases is the induction of oral tolerance [11].
Oral tolerance is a natural state of a decreased 
immunoresponse to the previously fed antigen. 
The mechanism induces tolerance toward ingested 
antigens, which are normally encountered in the 
body (e.g. commensal bacteria, food). The phenom-
enon of oral tolerance has been applied for ovalbu-
min-induced anaphylaxis, contact hypersensitivity or 
the suppression of antibody production. The same 
approach has been also proposed for the treatment 
of autoimmune diseases, and many preclinical trials, 
including MS therapy, have been conducted [11,37,38]. 
In most of those trials, myelin basic protein (MPB) 
or its fragments served as the antigen, and all were 
shown to reduce the clinical symptoms of induced 
experimental allergic encephalomyelitis (EAE) [15,26]. 
However, MBP is not the only antigen that is consid-
ered to be immunogenic in MS. Antibodies directed 
against proteolipid protein (PLP) and myelin oligo-
dendrocyte glycoprotein (MOG) have been detected 
in the cerebrospinal fluid of patients with MS [1,17]. 
Previously, in our laboratory, experiments with the 
use of pig spinal cord hydrolysate as the source of 
broad spectrum of myelin antigens to evoke oral tol-
erance in rats were performed [18]. In the presented 
experiment, we decided to use the most encephalo-
genic fragments of these three proteins, MBP85-97, 
PLP139-151 and MOG35-55, to induce a state of oral 
tolerance [2,23].
Since peptide synthesis is expensive and involves 
many complicated chemical procedures, other tech-
niques for obtaining peptides are desirable. One 
example is the application of food-grade lactic acid 
bacteria (LAB) as biofactories for the production of 
heterologous proteins [28]. Lactic acid bacteria are 
present in fermented foods, are safe for human and 
animal consumption, and are extensively devel-
oped as live antigen delivery systems. Heterologous 
expression of therapeutic proteins, such as enzymes, 
cytokines or antigens, allows the broad use of these 
bacteria in various applications [5]. For our purposes, 
we designed recombinant Lactococcus lactis strains 
for use as a mucosal antigen delivery system. As LAB 
are present naturally in the gastrointestinal tract, we 
aimed to develop a  minimally invasive method to 
induce oral tolerance that could be further applied 
for MS treatment. 
In our experiments, EAE was applied as an animal 
model of MS. As EAE is a  predominantly used MS 
model that is based on autoimmunological aspects 
of the disease, it was appropriate for our investiga-
tions. Also Lewis rats used in this study are com-
monly employed in such experiments, being one of 
the strains susceptible for EAE [23,39].
Our previous results demonstrated that feeding 
animals a mixture of L. lactis lysates producing MBP85-
97, PLP139-151 and MOG35-55, in a twenty-fold but 
not a  four-fold feeding scheme, could diminish the 
clinical symptoms of EAE [19]. In this study, we exam-
ined the influence of feeding L. lactis lysates on histo-
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pathological changes in the CNS and serum cytokine 
levels in rats with EAE.
Material and methods
Animals
Three-month-old female Lewis rats, provided by 
the Mossakowski Medical Research Centre, Polish 
Academy of Sciences, Warsaw, Poland, weighing 
approximately 180 g were used in the study. The ani-
mals were provided with food and water ad libitum 
unless otherwise required. Experiments were con-
ducted in accordance with EU Directive 2010/63/EU 
for animal experiments and based on the consent of 
the Fourth Local Ethics Committee for Animal Exper-
iments in Warsaw (Act no. 66/2010 of 08.10.2010).
Bacterial strains and plasmids 
Recombinant L. lactis derivatives of the natural iso-
late IBB360, and plasmids that were used in this work 
are listed in Table I. Construction of the pIL253:PptcB 
recombinant vectors expressing myelin antigens 
MBP85-97, PLP139-151 and MOG35-55 have been des-
cribed elsewhere [19].
Preparation of whole-cell lysates of 
recombinant lactococci
Recombinant lactococci were prepared for intra-
gastric administration as follows. Cells were grown 
overnight at 30°C in M17 medium [36] supplement-
ed with 0.5% cellobiose and erythromycin (5 µg/ml). 
Subsequently, cells were harvested (8000 g, 10 min., 
4°C) and washed once with 0.9% NaCl. Cells were 
then suspended in 0.9% NaCl and disrupted 3 times 
for 1 min using the MiniBeadbeater (BioSpec Prod-
ucts) and 106-µm glass beads (Sigma). Adequate 
dilutions of cell lysates were generated that corre-
sponded to doses of 103 and 106 colony forming units 
(CFUs). Single doses were frozen in Eppendorf tubes 
in liquid nitrogen and stored at –20°C until use.
Study design
A total number of 36 animals were randomly divid-
ed into 6 groups, consisting of 6 rats each. Animals 
with evoked EAE were fed intragastrically. Animals 
were given preparations containing either bacte-
ria with empty vector (pIL253:PptcB) or a  mixture 
of bacteria producing myelin peptides (MOG35-55, 
MBP85-97 and PLP139-151). Both preparations were 
administered in two doses. As reference, a group of 
animals with EAE, not receiving the bacteria prepa-
rations was created. Non-treated animals served as 
a control group. For the time diagram of the experi-
ment see Figure 1. 
Animal feeding
Using a  gauged pointed needle, animals were 
fed intragastrically with bacteria preparations 
once daily for 20 consecutive days. Animals were 
deprived of food two hours before administra-
tion of the bacteria. The administered prepara-
tions contained whole-cell L. lactis lysates diluted 
accordingly in 0.5 ml saline to obtain a dose of 103 
or 106 CFU/rat.
Table I. Strains and plasmids
Strain Genotype Source
Lactococcus lactis
IBB360 Natural isolate, characterized as an autolytic strain IBB PAS collection
Plasmids
pIL253:PptcB EryR, pIL253 derivative with regulated ptcB gene promoter region [19]
pIL253:PptcB:MOG35-55 EryR, pIL253 derivative with ptcB gene promoter, expressing MOG35-55 antigen [19]
pIL253:PptcB:MBP85-97 EryR, pIL253 derivative with ptcB gene promoter, expressing MBP85-97 antigen [19]
pIL253:PptcB:PLP139-151 EryR, pIL253 derivative with ptcB gene promoter, expressing PLP139-151 antigen [19]
 –10 0 10 14
  ↑  ↑
       Experimental allergic Tissue collection 
 encephalomyelitis induction
Feedeing 20× Day of experiment
Fig. 1. Time diagram of experiment.
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Experimental allergic encephalomyelitis 
Animals were immunized on the 10th day of feed-
ing. The day of immunization was defined as 0 days 
post-immunization (DPI). EAE was evoked as follows: 
slightly anesthetized animals (intraperitoneal injec-
tion with sodium brietal, Lilly) were injected intra-
dermally into the hind paws with 100 µl (per paw) 
of the immunization mixture. The mixture contained 
guinea pig spinal cord homogenate (50% homoge-
nate in PBS) with Freund’s adjuvant (1 : 1) and Myco-
bacterium tuberculosis (4 mg/ml). The components 
were mixed well before application. 
Material collection 
At 15 DPI, the animals were anesthetized (0.67 ml/
kg ketamine + 0.5 ml/kg xylazine i.p., Vetoquinol Bio-
wet) and, after blood collection, perfused transcardi-
ally with 4% paraformaldehyde. Lumbar and cervical 
segments of spinal cords were collected from the 
spinal canal for histopathological analysis. Serum 
was obtained from the collected blood.
Histopathological analysis
The collected spinal cord fragments were embed-
ded in paraffin and cut into 8-µm-thick slices. Cresyl 
violet staining (1% water solution) was performed for 
cell exposure. A  series of labeling experiments were 
also performed using the sections with the following 
antibodies: anti-T cells (Anti-CD45R0, DAKO), anti-
GFAP (anti-glial fibrillary acidic protein, DAKO) and 
anti-endogenous albumin (rabbit IgG fraction against 
rat albumin, MP Biomedicals). The procedure was per-
formed as follows: using dewaxed slices, endogenous 
peroxidase was blocked with 3% hydrogen peroxide, 
and the background was blocked with 10% albumin. 
After incubation with the primary antibodies, the sec-
tions were washed and then incubated with a second-
ary antibody coupled to biotin. After washing, strepta-
vidin coupled to peroxidase was applied followed by 
a  chromogen. The sections were then stained with 
Mayer’s hematoxylin. The chemicals were supplied by 
DAKO. The sections were analyzed using a light micro-
scope (AH3, Olympus) and images were obtained 
using a designated camera (3-35AD-4, Olympus).
Morphometric analysis 
The morphometric analysis was conducted using 
both lumbar and cervical spinal cord segment sec-
tions stained with Cresyl violet. The area of the whole 
spinal cord cross-section and the area occupied by 
the inflammatory infiltrate were measured to deter-
mine the ratio, which is presented as the percentage 
of the slice area occupied by the inflammatory infil-
trate.
Measurement of cytokine levels
In serum obtained from collected blood, cytokine 
levels (IL-1b, IL-10, TNF-α and IFN-γ) were analyzed. 
Analysis were made using the Bio-Plex Rat Cytokine 
Assay (Bio-Rad, Poland) according to the protocol 
supplied by the manufacturer (Bio-PlexTM Cytokine 
Assay Instruction Manual, Bio-Rad, Poland). Measu-
rements were made using Luminex Bio Plex 200 
analyzer, equipped with the software Manager ver-
sion 5.0. (Bio-Rad, Poland). 
Statistical analysis
The results are presented as means ± SD. Statis-
tical assessments were performed using the Mann- 




Spinal cord cross-sections from control animals 
showed no signs of inflammation (Fig. 2A and D). 
Inflammatory infiltrates that were visible in both the 
gray and white matter of the spinal cord in rats with 
evoked EAE (Fig. 2B) diminished after oral administra-
tion of both doses of L. lactis lysates (Fig. 2C). Moreover, 
there were no visible differences between the intensi-
ty of the infiltrates in rats fed preparations containing 
lysates of bacteria producing myelin peptides and con-
trol preparations (data not shown). We also noticed 
that the infiltrates in animals fed bacterial lysates 
(both the control and the L. lactis producing myelin 
peptides preparations) had a  reduced abundance of 
inflammatory cells (Fig. 2F) compared with rats with 
EAE (Fig. 2E), yet they occupied a similar area.
Anti-GFAP labeling revealed active astrocytes in 
both the gray and white matter of the spinal cord. 
In untreated rats, a weak reaction was observed, and 
the astrocytes displayed short tabs and insufficient 
cytoplasm (Fig. 2G), whereas rats with induced EAE 
were characterized by active astrocytes with long, 
branched tabs (Fig. 2H). After oral administration 
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of L. lactis lysates, the number of active astrocytes 
increased in rats with EAE (Fig. 2I).
Anti-endogenous albumin labeling revealed albu-
min in the perivascular area of rats with induced EAE 
(Fig. 3A). T cells were observed in the area occupied 
by inflammatory infiltrates (Fig. 3B).
Morphometric analysis
A  morphometric analysis was conducted to 
assess the area of the spinal cord cross-section 
occupied by inflammatory infiltrates. No significant 
differences were observed between groups of fed or 
non-fed rats with EAE. Animals in the experimental 






























Fig. 2. Spinal cord cross-sections. Cresyl violet staining (A–F); inflammatory infiltrates are indicated by arrows. 
Anti-GFAP labeling (G–I); astrocytes are indicated by arrows. Non-treated animals (NT), animals with induced 
experimental allergic encephalomyelitis (EAE), animals with EAE fed bacteria producing myelin peptides 
(Lactococcus lactis), n = 6.
Fig. 3. Spinal cord cross-sections. Anti-endogenous albumin labeling (A). Anti-T cell labeling (B), n = 6.
A B
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groups presented very large individual differences 
in the infiltration area, resulting in highly dispersive 
results. Therefore, the changes observed in the area 
occupied by inflammatory infiltrates can only be 
described as trends and were similar for both cervi-
cal and lumbar spinal cord segments (Fig. 4A and B). 
In rats that received a lower dose of the lysate (103) 
of myelin peptide-producing bacteria, inflammatory 
infiltrates occupied a small area of the spinal cord 
cross-section, while higher dose preparations of 
both control (106 C) and myelin peptide-producing 
bacteria (106) lead to a slight increasing trend in the 
area occupied by inflammatory infiltrates in compar-
ison to non-fed rats with EAE.
Cytokine levels 
The induction of EAE in rats resulted in elevat-
ed levels of IL-1b, IL-10, TNF-α and IFN-γ compared 
with non-treated animals (Fig. 5A-D). Oral adminis-
tration of L. lactis preparations (control and bacteria 
producing myelin peptides) at both doses decreased 
IL-1b, IL-10 and TNF-α to levels that were similar to 
non-treated animals (Fig. 5A-C). The same effect 
was observed for rats that received control bacte-
rial preparation. However, in the group that was fed 
lysates from myelin-producing bacteria, the level of 
IFN-γ remained elevated and even increased slightly 
following the administration of preparation at the 
higher dose (Fig. 5D).
Discussion
Multiple sclerosis is a disease of unknown etio-
logy. As a  result, only the symptoms, and not the 
cause, can be treated. Current MS therapies include 
mostly non-specific, systemic immunosuppression, 
which is not free from side effects or can simply 
be inefficient. Other therapies may be more ade-
quate, but they may also cause severe side effects 
(e.g. natalizumab) [42]. Our intention in the present 
study was to exploit the naturally occurring state of 
oral tolerance for the treatment of MS. As MS is an 
autoimmune disease in which autoreactive T lym-
phocytes destroy the myelin sheath, the induction of 
oral tolerance, which decreases the systemic immu-
noresponse to previously fed antigen, may be an 
interesting therapeutic alternative. Gut-associated 
lymphoid tissue (GALT) produce anti-inflammatory 
cytokines providing the immunosuppressive envi-
ronment, helping to maintain the state of tolerance 
for antigens from food or commensal bacteria. Den-
dritic cells in the GALT present the gut-derived anti-
gens to naïve T cells in Peyer’s patches, what results 
in differentiation of T cells into regulatory T cells 
(Tregs) producing IL-10 and TGF-β, or internalization 
of TCR leading to anergy. Thus, orally administered 
fragments of myelin peptides induce, depending on 
the antigen dose, active suppression (inhibiting of 
Th1-dependent immunoresponse) or anergy/clonal 
deletion of responsive T lymphocytes (both Th1 and 
Th2) in the mucosal immune system [4,27,40]. Aner-
gic T cells are not able to migrate from the site of 
tolerance induction, and remaining in the GALT pro-
duce anti-inflammatory cytokines. Tregs induced in 
the Peyer’s patches pass into the bloodstream and 
spread the antigen-specific tolerance throughout the 
body. Additionally, apoptosis of autoreactive T cells 
is induced in the thymus after oral administration 



































 EAE 103 C 106 C 103 106
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       Experimental group
Fig. 4. Percentage of the section area occupied by 
inflammatory infiltrates. Cervical segment of spinal 
cord (A). Lumbar segment of spinal cord (B), n = 6.
A
B
255Folia Neuropathologica 2016; 54/3
Effect of recombinant Lactococcus lactis producing myelin peptides on neuroimmunological changes in rats with experimental allergic 
encephalomyelitis
a  diminished immunoresponse against myelin pep-
tides. Such an approach is anticipated to lead to an 
antigen-specific, non-systemic, non-specific immu-
nosuppression for the treatment of MS. In addition 
to oral tolerance, mucosal-associated tolerance (e.g. 
respiratory tract), generally known as mucosal tol-
erance, has been considered for many decades as 
a  potential approach for the treatment of illnesses 
such as uveitis, diabetes, rheumatoid arthritis or aller-
gy [38,41]. Immunological tolerance is an important 
mechanism that protects the organism from devel-
oping an immunoresponse to the exogenous anti-
gens that constantly contact the mucosa, by treating 
them as self-antigens. Oral tolerance in particular is 
responsible for maintaining tolerance to dietary anti-
gens and gut microflora. Lactococcus lactis bacteria 
are non-invasive, non-pathogenic and non-colonizing 
microorganisms with a GRAS (Generally Regarded As 
Safe) status. There is a large amount of evidence sup-
porting the utility of these bacteria as heterologous 
protein expression systems. Recombined, leptin-se-
creting L. lactis administered intranasally in mice 
resulted in a decrease in body mass and food intake 
[6]. Additionally, feeding with ovalbumin-secreting 
L. lactis has been reported to induce ovalbumin tol-
erance in mice. Furthermore, mice that received 
L. lactis alone were able to mount a slight immune 
response, indicating that this bacterial species itself 
can enhance the induction of oral tolerance [16,25]. 
We have previously shown that twenty-fold, but 
not four-fold, oral administration of a  mixture of 
lysates from L. lactis producing MBP85-97, PLP139-151 
and MOG35-55 in two doses of 103 and 106 CFU per 
dose reduces clinical symptoms and body mass drop 
in rats with EAE [19]. Here, we describe the effects 
of bacterial lysates on some neuroimmunological 
parameters of induced EAE, an animal model of MS. 
During the progression of EAE, the blood-brain barrier 
opens. This phenomenon is consistent with the theo-
ry regarding the mechanism responsible for the devel-
opment of MS, in which autoreactive T cells migrate 
into the CNS and induce an inflammatory response 
against myelin epitopes [13,24]. Our histopathologi-
cal analysis of the spinal cord cross-sections demon-
strated that evoking EAE resulted in the appearance 
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nous albumin labeling revealed its proximity to the 
vessels, confirming the opening of the blood-brain 
barrier. T-cell labeling showed that the infiltrates 
consisted of those immune cells. In our experiments, 
the inflammatory process observed after evoking 
EAE in rats was diminished by oral administration of 
L. lactis lysates. The decrease in inflammation inten-
sity was manifested by a reduced number of immune 
cells rather than by a smaller infiltration surface.
Anti-GFAP labeling was performed to expose 
active astrocytes. The induction of EAE resulted in an 
increase in the activity of a greater number of astro-
cytes, as compared with control rats, and feeding 
the animals with bacterial lysates further increased 
the number of these cells. This phenomenon could 
account for the increased astrocyte proliferation 
associated with repair processes and glial scar for-
mation in the CNS [26,30].
Serum cytokine levels were measured to deter-
mine the peripheral immunological state of the ani-
mals [20,31,33]. The results showed that the induc-
tion of EAE resulted in an increase in all measured 
cytokine levels, including both pro- and anti-inflam-
matory cytokines. Feeding animals with recombi-
nant L. lactis lysates decreased IL-1b, IL-10 and TNF-α 
to the levels detected in non-treated animals, which 
could imply that animals fed bacterial preparations 
did not develop an immune reaction. However, this 
explanation is inconsistent with the histopatho-
logical analysis showing infiltration into the CNS. 
CNS inflammation must be a  result of a  peripher-
al process because the immunization mixture was 
injected peripherally (paw pads). Therefore, it is more 
likely that our results capture the moment when the 
inflammatory process was completely cleared in the 
periphery but still present in the CNS. Differences in 
the reaction time of the peripheral versus the central 
immune system may result from the initial induction 
of antigen tolerance in the gut mucosa, followed by 
the periphery and then the CNS [29].
Interesting effects have been documented with 
respect to IFN-γ. After EAE induction, IFN-γ was ele-
vated in comparison to non-treated animals, and 
feeding with control bacterial preparations resulted 
in decreased IFN-γ levels. However, when the animals 
were fed either dose of the bacterial lysate producing 
myelin peptides, the level of IFN-γ remained elevated. 
Previous investigations have shown that IFN-γ influ-
ences apoptosis of autoreactive T cells by astrocytes 
[14,32], which may underlie the reduced number of 
inflammatory cells observed in the infiltrates in rats 
fed bacterial lysates.
An important observation was made with res-
pect to the effect of oral administration of lysates 
containing L. lactis cells carrying the empty vector 
(pIL253:PptcB). Results showed that the control 
preparation may produce a similar but less intense 
effect in rats as lysates from bacteria producing 
myelin antigens. It is known that lactococcal cells 
themselves are able to enhance immunotolerance 
in mucosa. Our observations are similar to those of 
Lavasani et al. [22] who showed that, due to their 
immunomodulatory activity and ability to induce 
regulatory T cells, three probiotic lactic acid bacte-
ria strains (L. paracasei, L. plantarum DSM 15312 and 
L. plantarum DSM 15313) could be helpful for the 
treatment of autoimmune diseases.
Difficulties associated with the development of 
effective MS therapy are linked to the observation 
that almost every patient presents a unique course 
of the disease [21]. Similarly, in experimental animals, 
even inbred animal lines, the clinical symptoms will 
differ among individual cases. In our trials, EAE was 
induced using guinea pig spinal cord homogenate 
as the source of myelin antigens to imitate MS, in 
which many encephalogenic antigens are believed to 
play a role. Our previous study has also shown that 
the three main myelin peptide fragments selected to 
induce oral tolerance appear to be effective [19].
Experimental results in this work indicate that 
L. lactis is a  good antigen delivery system for the 
induction of oral tolerance in animals with EAE. This 
notion is confirmed not only by the diminished clin-
ical symptoms of the ongoing disease but also by 
the decreased inflammatory activity. We suggest 
that oral administration of lysates from recombinant 
L. lactis cells accelerates the resolution of peripher-
al inflammation, decreases the intensity of inflam-
mation in the CNS, and boosts the repair process. 
Considered together, these phenomena may eluci-
date a perspective for further development of this 
approach in MS therapy. 
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